HWP
NRXP icon

Hibernia Wealth Partners’s NRX Pharmaceuticals NRXP Stock Holding History

Hibernia Wealth Partners’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-25
Closed -$65 – 245
2023
Q3 		$65 Buy
+25
New +$83 ﹤0.01% 347

Other funds holding NRXP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
OWMIAS
One Wealth Management Investment & Advisory Services Miami Beach, Florida $95.3M AUM 25.31% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Hibernia Wealth Partners's NRXP Position: Q4 2023 in Review

Hibernia Wealth Partners sold out of NRX Pharmaceuticals (NRXP) in Q4 2023, closing a stake of 25 shares — an estimated $65 sold.

Hibernia Wealth Partners first reported a position in NRXP in Q3 2023 and held it in 1 quarter. The position peaked at $65 in Q3 2023. 30 funds tracked by Wall St. Rank hold NRXP as of Q4 2023.

  • Hibernia Wealth Partners reported no remaining NRX Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Hibernia Wealth Partners sold 25 NRX Pharmaceuticals shares in Q4 2023, an estimated $65.
  • Hibernia Wealth Partners first reported a position in NRX Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Hibernia Wealth Partners's NRX Pharmaceuticals position peaked at $65 in Q3 2023.
  • 30 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q4 2023.

Based on Hibernia Wealth Partners's 13F filing for Q4 2023, filed 19 Jan 2024.